SR-3029 is primarily investigated for its potential therapeutic applications in the field of medicine. It is known to act as an inhibitor of casein kinase 1 (CK1), which plays a role in various cellular processes, including circadian rhythms, cell division, and apoptosis. Due to its mechanism of action, SR-3029 is being studied for its ability to modulate circadian clock function, which could be beneficial in treating sleep disorders, jet lag, and other conditions linked to circadian rhythm disruptions. Additionally, its role in inhibiting CK1 has sparked interest in its potential use in cancer research, as CK1 is often implicated in tumor growth and progression. Early studies suggest that SR-3029 may help in slowing down or preventing the proliferation of certain cancer cells, making it a candidate for further development in oncology. Its application in neurodegenerative diseases is also being explored, given the connection between CK1 and pathways involved in neurodegeneration. Overall, SR-3029 holds promise as a versatile compound in both circadian biology and disease treatment research.